Business Wire

NC-BIOVENTUS

22.9.2020 16:32:10 CEST | Business Wire | Press release

Share
Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide

Bioventus , a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE , its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.

Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One® .1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4

DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ , to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.

“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.

Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.

*DUROLANE SJ is not available in the US.

Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.

NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.

1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis . 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage . 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol . 2019;37 Suppl 120(5):3-6.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SoftBank Robotics Expands AI & Robotics Solutions for Foodservice in EMEA30.9.2026 09:30:00 CEST | Press release

Showcasing Advanced Cooking Solutions and AI-Powered Service Robotics at EquipHotel 2026 in Paris SoftBank Robotics UK Ltd. today announced that it will showcase its AI & Robotics solutions for foodservice at EquipHotel 2026, taking place in Paris, France, from 2 to 5 November 2026, as part of its efforts to expand foodservice automation initiatives across the EMEA region. Hospitality and foodservice operators continue to face operational challenges, including labour shortages, difficulties in recruiting skilled staff, rising costs, inconsistent food quality, and food waste. SoftBank Robotics aims to help address these challenges through robotics and automation, supporting more efficient, consistent and flexible foodservice operations. STEAMA is a steam-based cooking robot that uses high-pressure, high-temperature steam to prepare frozen noodle dishes in about 90 seconds. Designed for simple, one-touch operation, it helps operators consistently serve freshly prepared dishes with ease.

IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 09:00:00 CEST | Press release

New innovation from IFF’s Science of Performance platform offers greater transparency and olfactive performance for fine fragrance IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the

PREPAR-VIE Selects Clearwater Analytics to Modernize and Replace Its Investment Management System30.9.2026 09:00:00 CEST | Press release

French life insurer selects Clearwater’s front-to-back platform to support the transition Clearwater Analytics today announced that PREPAR-VIE, a life insurance company managing more than €9 billion in assets, has selected Clearwater as its technology partner to unify its front-to-back investment operations within a single, integrated platform. According to S&P Global Ratings, France is among the key drivers of life insurance growth in Europe, as insurers continue to shift their offerings toward unit-linked products. In this context, the best-positioned players are those with real-time visibility across the entire investment lifecycle. With Clearwater, PREPAR-VIE will simplify its investment operations and streamline reporting for both its general account and its unit-linked investments within a single platform. Clearwater covers the entire investment lifecycle — from portfolio and order management to multi-standard investment accounting (French GAAP and IFRS), reconciliation, and unit

SES and Sky Sign Multi-Year Satellite Capacity Agreement30.9.2026 08:50:00 CEST | Press release

The renewal extends the companies' partnership into next decade, supporting premium television services across the UK and Ireland SES and Sky have extended their long-standing partnership in a new multi-year agreement for direct-to-home (DTH) satellite services across the United Kingdom and Republic of Ireland, running into the next decade. Under the agreement, Sky will continue to leverage SES's satellite capacity at the 28.2 degrees East orbital position to deliver television services to millions of households across the region. The renewal extends a partnership that dates to 1988 and reinforces satellite's ongoing role in delivering premium television experiences at scale. “As we give customers more choice in how they access Sky, satellite continues to play an important role in how we deliver our services to customers across the UK and Ireland,” said Nick Herm, Group Chief Operating Officer, Sky. “This agreement with SES provides the reliability, reach and service quality we need to

rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 08:30:00 CEST | Press release

The launch brings rhode into physical retail across Europe, previously only being available for purchase in the region through rhodeskin.com rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye